Acumen Pharmaceuticals presented updated data at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference regarding its innovative pTau217 assay for screening participants in the Phase 2 ALTITUDE-AD clinical trial of sabirnetug. The study demonstrated that this enrichment screening approach leads to a higher proportion of eligible participants.
The pTau217 screening method resulted in a more efficient participant selection process, reducing the need for unnecessary amyloid PET scans or lumbar puncture procedures. This approach improved enrollment efficiency, with 74% of participants with p-tau217 ">=0.15 pg/mL" meeting amyloid burden eligibility, compared to 40% in the Phase 1 INTERCEPT-AD trial.
This advancement streamlines the trial enrollment process, potentially reducing burden for patients and clinical trial staff. The company expects to complete enrollment in the first half of 2025, with this screening strategy contributing to the pace of progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.